Clovis Oncology
Clovis Oncology is a publicly traded biopharmaceutical company that acquires, develops, and commercializes cancer treatments. Founded in 2009 and headquartered in Boulder, Colorado, the company focuses on bringing oncology therapeutics to market under NASDAQ ticker CLVS.
- Company typePrivate
- Founded2009
- HeadquartersBoulder, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Clovis Oncology does
Clovis Oncology is a publicly traded biopharmaceutical company focused on acquiring, developing, and commercializing cancer treatments. Founded in 2009 and headquartered in Boulder, Colorado, the company operates as a for-profit specialty oncology developer listed on NASDAQ under the ticker CLVS. The firm's stated business model centers on identifying oncology assets, advancing them through development, and bringing them to market as commercial therapeutics.
The company's organizational footprint spans 101 to 250 employees, consistent with a commercial-stage or late-clinical-stage biopharmaceutical operation. Its executive team is structured for regulatory-driven pharmaceutical commercialization, with dedicated leadership for Regulatory Affairs & Technology Operations, Human Resources, Legal (General Counsel), and Finance (CFO), under President and CEO Patrick Mahaffy. The early capitalization reflects confidence from top-tier healthcare venture investors, including a $145 million Series A in May 2009 led by a consortium of Aberdare Ventures, Abingworth, Domain Associates, Frazier Healthcare Partners, New Enterprise Associates, ProQuest Investments, and Versant Ventures, followed by strategic investment from Pfizer Venture Investments and Aisling Capital in 2011.
The commercial mechanics of Clovis Oncology's business — specific drug products in market, pricing models, distribution channels, payer mix, and revenue mechanics — are not disclosed in the available source material. The company's short description frames its model as acquiring, developing, and commercializing cancer treatments, implying a hybrid of in-licensing and internal development with subsequent specialty or broad oncology distribution, but the absence of product-level, pricing, or channel detail in the input data limits further specificity.
Clovis Oncology firmographics
Firmographics- Name
- Clovis Oncology
- Website
- https://clovisoncology.com
- Company type
- Private
- Founded year
- 2009
- Headcount range
- 101–250 employees
- Short description
- Clovis Oncology is a publicly traded biopharmaceutical company that acquires, develops, and commercializes cancer treatments. Founded in 2009 and headquartered in Boulder, Colorado, the company focuses on bringing oncology therapeutics to market under NASDAQ ticker CLVS.
- Ownership category
- akta.pro rank
Clovis Oncology industry classification
Industry- Product category
- Oncology Pharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Oncology Specialty Pharmaceuticals (HLAIACAA)
Keywords
Where Clovis Oncology is headquartered
LocationHeadquarters
- HQ city
- Boulder
- HQ country
- United States
- HQ region
- North America
Markets served
Clovis Oncology business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Clovis Oncology product offering
Product offeringCore offering
Clovis Oncology is a biopharmaceutical company that acquires, develops, and commercializes oncology treatments for cancer patients. The company focuses on identifying, in-licensing, and advancing novel cancer therapeutics through clinical development and regulatory approval, ultimately bringing approved products to market.
Differentiator
Problem solved
Functional benefit
Products and services
- Cancer treatments portfolio Acquired, developed, and commercialized oncology therapeutics for the treatment of various cancer types, targeting oncologists, hospitals, and cancer treatment centers.
Companies that use Clovis Oncology
Customer profileIdeal customer profiles2 records
Clovis Oncology technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Clovis Oncology partnerships and signals
Strategic signalRecent moves4 records
Expansion highlights2 records
Clovis Oncology competitors and assessment
Company assessmentDirect peers
- MEI Pharma: Clinical-stage oncology biopharmaceutical company developing cancer therapies. Comparable in therapeutic focus and development-stage specialty pharma positioning.
- Spectrum Pharmaceuticals: Specialty oncology biopharmaceutical company focused on acquiring, developing, and commercializing cancer treatments. Highly comparable business model and therapeutic focus.
- Exelixis: Specialty oncology biopharmaceutical company focused on developing and commercializing cancer treatments. Comparable in therapeutic focus and commercial-stage oncology business model.
- Puma Biotechnology: Specialty biopharma focused on oncology drug development and commercialization. Comparable in scale, therapeutic focus, and clinical/commercial-stage operating model.
- Rigel Pharmaceuticals: Specialty biopharmaceutical company developing oncology and immunology treatments. Comparable in scale, therapeutic adjacency, and commercial-stage operations.
- Halozyme Therapeutics: Biopharmaceutical company with oncology-focused product portfolio and proprietary drug delivery technology. Comparable as a specialty oncology biopharma.
Broad incumbents
- Incyte Corporation: Larger specialty biopharmaceutical company with significant oncology franchise alongside other therapeutic areas. Comparable as an oncology-focused commercial-stage biopharma with broader portfolio.
- Seagen (Seattle Genetics): Established oncology-focused biopharmaceutical company developing and commercializing cancer therapeutics. Comparable therapeutic focus and specialty pharma business model.
Emerging players
- CytomX Therapeutics: Clinical-stage oncology biopharmaceutical company developing novel cancer therapeutics. Comparable therapeutic focus at earlier development stage.
- Pieris Pharmaceuticals: Clinical-stage biopharmaceutical company with oncology-focused pipeline. Comparable in therapeutic focus and biopharma development model.
Market position
Strengths3 records
Weaknesses3 records
Competitive moat3 records
Key risks4 records
Key highlights5 records
Customer concentration
Clovis Oncology social profiles
Digital presenceClovis Oncology financial estimates
Financial estimateRevenue estimate
Valuation estimate
Clovis Oncology leadership team
Management profileNumber of profiles
Profiles5 records
Clovis Oncology funding detail
Funding detailFunding overview
Funding rounds2 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Clovis Oncology M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Clovis Oncology
What does Clovis Oncology do?
Clovis Oncology is a biopharmaceutical company that acquires, develops, and commercializes oncology treatments for cancer patients. The company focuses on identifying, in-licensing, and advancing novel cancer therapeutics through clinical development and regulatory approval, ultimately bringing approved products to market.
When was Clovis Oncology founded?
Clovis Oncology was founded in 2009. It employs 101 to 250 people.
Where is Clovis Oncology based?
Clovis Oncology is headquartered in Boulder, United States, in the North America region.
Who are Clovis Oncology's main competitors?
Direct peers on record are MEI Pharma, Spectrum Pharmaceuticals, Exelixis, Puma Biotechnology, Rigel Pharmaceuticals and Halozyme Therapeutics. Broad incumbents are Incyte Corporation and Seagen (Seattle Genetics). Emerging players are CytomX Therapeutics and Pieris Pharmaceuticals.
Does Clovis Oncology have an API?
No public API is recorded for Clovis Oncology.
What industry is Clovis Oncology in?
Clovis Oncology's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.